Clinical and pathologic features in SOX11− and SOX11+ tumors in the whole cohort of patients with MCL
| Clinical and pathologic features . | SOX11− cases, n = 13 (%) . | SOX11+ cases, n = 160 (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 71.4 (48.4-89.9) | 69.7 (36.2-89.2) | |
| Male sex | 10/13 (77) | 108/160 (68) | NS |
| Age > 65 y | 11/13 (85) | 101/160 (63) | NS |
| B symptoms | 6/13 (46) | 59/154 (38) | NS |
| ECOG score ≥ 2 | 1/12 (8) | 6/152 (4) | NS |
| Nodal presentation (> 4 nodal sites) | 6/12 (50) | 99/157 (63) | NS |
| Splenomegaly | 5/10 (50) | 73/146 (50) | NS |
| Ann Arbor stage IV | 13/13 (100) | 129/159 (81) | NS |
| WBC count > 10 × 109/L | 7/13 (54) | 47/154 (31) | NS |
| Lymphocyte count > 5 × 109/L | 7/13 (54) | 38/153 (25) | .045 |
| High serum LDH level | 9/12 (75) | 58/149 (39) | .029 |
| MIPI high risk | 6/8 (75) | 57/126 (45) | NS |
| Ki-67 high (≥ 30%) | 5/12 (42) | 54/142 (38) | NS |
| Ki-67 very high (≥ 50%) | 1/12 (8) | 25/142 (18) | NS |
| Blastoid structure | 2/12 (17) | 15/145 (10) | NS |
| p53 positivity > 20% of cells by IHC | 9/13 (69) | 24/152 (16) | < .001 |
| CD23 positivity by flow cytometry | 7/12 (58) | 64/137 (47) | NS |
| Indolent disease* | 2/13 (15) | 15/157 (10) | NS |
| Intense treatment without ASCT | 1/12 (8) | 3/160 (2) | NS |
| ASCT | 1/12 (8) | 31/160 (19) | NS |
| Median overall survival (days)† | 494 | 1180 | .014 |
| Clinical and pathologic features . | SOX11− cases, n = 13 (%) . | SOX11+ cases, n = 160 (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 71.4 (48.4-89.9) | 69.7 (36.2-89.2) | |
| Male sex | 10/13 (77) | 108/160 (68) | NS |
| Age > 65 y | 11/13 (85) | 101/160 (63) | NS |
| B symptoms | 6/13 (46) | 59/154 (38) | NS |
| ECOG score ≥ 2 | 1/12 (8) | 6/152 (4) | NS |
| Nodal presentation (> 4 nodal sites) | 6/12 (50) | 99/157 (63) | NS |
| Splenomegaly | 5/10 (50) | 73/146 (50) | NS |
| Ann Arbor stage IV | 13/13 (100) | 129/159 (81) | NS |
| WBC count > 10 × 109/L | 7/13 (54) | 47/154 (31) | NS |
| Lymphocyte count > 5 × 109/L | 7/13 (54) | 38/153 (25) | .045 |
| High serum LDH level | 9/12 (75) | 58/149 (39) | .029 |
| MIPI high risk | 6/8 (75) | 57/126 (45) | NS |
| Ki-67 high (≥ 30%) | 5/12 (42) | 54/142 (38) | NS |
| Ki-67 very high (≥ 50%) | 1/12 (8) | 25/142 (18) | NS |
| Blastoid structure | 2/12 (17) | 15/145 (10) | NS |
| p53 positivity > 20% of cells by IHC | 9/13 (69) | 24/152 (16) | < .001 |
| CD23 positivity by flow cytometry | 7/12 (58) | 64/137 (47) | NS |
| Indolent disease* | 2/13 (15) | 15/157 (10) | NS |
| Intense treatment without ASCT | 1/12 (8) | 3/160 (2) | NS |
| ASCT | 1/12 (8) | 31/160 (19) | NS |
| Median overall survival (days)† | 494 | 1180 | .014 |
MCL indicates mantle cell lymphoma; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; LDH, lactate dehydrogenase; MIPI, MCL International Prognostic Index; IHC, immunohistochemistry; and ASCT, autologous stem cell transplantation.
Defined as not requiring treatment within 2 years from diagnosis. One SOX11− case got high-dose cytosine arabinoside (AraC) as CNS prophylaxis, 1 SOX11+ case got high-dose AraC with intention of ASCT but could not be transplanted, 2 SOX11+ cases with kidney dysfunction got high-dose AraC.
Excluding patients receiving ASCT (SOX11−, n = 1; SOX11+, n = 31).